Biohaven Pharmaceutical Holding Co Ltd. - Oct 3, 2022 Form 4 Insider Report for Biohaven Ltd. (BHVN)

Role: 10%+ Owner
Signature: /s/ George Clark, Attorney-in-Fact
Stock symbol: BHVN
Transactions as of: Oct 3, 2022
Transactions value $: $0
Form type: 4
Date filed: 10/5/2022, 05:40 PM
Previous filing: Sep 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Other	$0	+35.8M		$0.00	35.8M	Oct 3, 2022	Direct	F1
transaction	BHVN	Common Shares	Other	$0	-35.8M	-100%	$0.00^*	0	Oct 3, 2022	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance").
F2	On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer.

Content

On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance").

On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer.